SOURCE: In Ovations Holdings, Inc.

December 08, 2014 09:50 ET

In Ovations Holdings, Inc. Enters Into Sales and Marketing Agreement With Regulon, Inc. Expanding Its Cancer Detection Offerings to Include Cancer Treatment Solutions

DORAL, FL--(Marketwired - Dec 8, 2014) - In Ovations Holdings, Inc. (OTC PINK: INOH) has concluded negotiations and due diligence and has entered into a sales and marketing agreement with Regulon, Inc. ("Regulon") for the marketing and sale of Regulon's anti-cancer therapies. The parties will leverage INOH's access to markets including the Caribbean in order to broaden the awareness and sale of their cancer detection and treatment products. The global cancer market was $75-80 billion in 2013. Sales of platinum-based chemotherapy drugs (cisplatin, carboplatin, oxaliplatin) were $2.6 bn (in seven major pharmaceutical markets) in 2008.

Regulon designs and produces the following anti-cancer drugs: LipoPlatin™, LipoXal™, LipoVil-12™. Regulon has developed a unique liposome encapsulation technology applicable to drugs such as cisplatin, a cytotoxic agent, small molecules, peptides, proteins and viruses aiming at improving human lives and reducing the side effects of chemotherapy known to exacerbate the quality of life of cancer patients. Regulon is currently engaged in active sales.

Recent studies showed that platinum-based chemotherapy drugs share is growing. The platinum drug market is anticipated to increase tremendously after cisplatin, a cytotoxin agent, is replaced by Regulon's LipoPlatin™. Regulon is a private biopharmaceutical company committed to the discovery and development of nano-pharmaceutics in oncology which has raised over $30,000,000 in the private marketplace in countries including Greece, Cyprus, Austria, Turkey, Korea, Brazil, Taiwan, Israel, and Lebanon.

Teni Boulikas, PhD., President and CEO of Regulon, stated: "After establishing a solid base in Europe and breaking into the Asian market, we are pleased to partner with INOH. We view this relationship as symbiotic, offering INOH's clients cancer solutions from detection to treatment. We look forward to the introduction of Regulon's products to the Caribbean markets."

Mark Goldberg, Co-CEO of INOH, added: "After the recent phase of technology acquisition by INOH culminating in the launching of sputum cytology products, developed by Mel Ehrlich, Ph.D., reaching end-users is our primary goal." Co-CEO Rosendo Alvarez, III added, "We are thrilled to enter this association with Regulon and to augment our companies' offerings to purchasers of cancer-related technologies. The mutual introduction to additional markets is the beginning of a new phase with significant growth potential for both companies."

INOH's recently formed Medical Advisory Committee http://inovationsholdings.com/medical-advisory-board/  is a an integral part of its oversight of these projects.

A comprehensive evaluation of INOH's sputum cytology technology appears on its website: http://inovationsholdings.com/cytometry/

Regulon's comprehensive corporate and scientific profile can be viewed at http://www.regulon.org/

Background

INOH continues to pursue several potential business opportunities outside of the cancer-related field. Its subsidiary, Electro Verde, Inc., markets, in conjunction with Coordinated Systems International, the patented GradiLuxtm Total Lighting System Solution which can reduce electricity consumption and carbon emissions in municipal lighting systems worldwide. The Company is also engaged in a Caribbean-based marine-related eco-tourism and ocean search and recovery. It is a minority owner of Atmospheric Water Solutions, a company involved in water purification. INOH is also engaged in identifying and engaging in other opportunities for purposes of diversification and revenue generation.

Safe Harbor Statement:

Under the Private Securities Litigation Reform Act of 1995: This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

Contact Information